Satellos Bioscience (NASDAQ:MSLE) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPS

Satellos Bioscience (NASDAQ:MSLE) released its earnings results on Friday. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.02), Zacks reports.

Satellos Bioscience Trading Down 2.2%

Shares of MSLE traded down $0.16 during mid-day trading on Friday, hitting $7.01. 43,311 shares of the company’s stock were exchanged, compared to its average volume of 38,248. The firm’s fifty day simple moving average is $7.52. Satellos Bioscience has a twelve month low of $4.53 and a twelve month high of $13.39. The firm has a market capitalization of $146.02 million, a PE ratio of -4.52 and a beta of 1.60.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on MSLE shares. Guggenheim started coverage on shares of Satellos Bioscience in a research note on Tuesday, April 28th. They issued a “buy” rating and a $23.00 price target for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Satellos Bioscience in a research note on Monday. Wall Street Zen lowered shares of Satellos Bioscience from a “sell” rating to a “strong sell” rating in a research note on Saturday, April 25th. Zacks Research raised shares of Satellos Bioscience to a “hold” rating in a research note on Tuesday, February 10th. Finally, HC Wainwright increased their target price on shares of Satellos Bioscience to $11.00 and gave the company a “buy” rating in a research note on Monday, March 30th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Satellos Bioscience currently has an average rating of “Moderate Buy” and a consensus target price of $18.00.

Satellos Bioscience Company Profile

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.